美托洛尔联合门冬氨酸钾镁盐治疗老年缺血性心律失常的疗效及对患者心功能的影响
|
摘要
目的探讨美托洛尔联合门冬氨酸钾镁盐治疗老年缺血性心律失常的临床疗效及对患者心功能的影响。方法回顾性分析2016年8月至2017年9月于安康市中心医院心内科接受治疗的98例老年缺血性心律失常患者的临床资料,根据不同的药物治疗方法将患者分为对照组和观察组各49例。对照组患者给予美托洛尔单纯治疗,观察组患者在对照组基础上加用门冬氨酸钾镁盐联合治疗,疗程为一个月。比较两组患者的临床治疗效果和动态心电图疗效,并对治疗前后的心功能指标和心律失常指标进行比较。结果观察组患者治疗后的临床治疗总有效率为95.92%,明显高于对照组的81.63%,动态心电图疗效总有效率为91.84%,明显高于对照组的83.67%,差异均有统计学意义(P<0.05);治疗后观察组患者的左室收缩末期内径为(44.78±6.42) mm,较对照组的(50.58±6.83) mm下降明显,心输出量和左室射血分数分别为(5.30±0.97) L/min、(41.29±8.56)%,较对照组的(4.60±0.89) L/min和(31.86±5.93)%上升明显,差异均有统计学意义(P<0.05);治疗后观察组患者的房性期前收缩、室性期前收缩和交界性期前收缩次数下降程度分别为(1 621±354)次/24 h、(1 291±109)次/24 h、(117±34)次/24 h,下降程度明显高于对照组的(3 200±457)次/24 h、(2 469±360)次/24 h、(262±46)次/24 h,差异均有统计学意义(P<0.05)。结论美托洛尔联合门冬氨酸钾镁盐治疗老年缺血性心律失常患者有利于改善患者的心功能,临床治疗效果显著,值得临床推广使用。
Objective To explore the efficacy of metoprolol combined with potassium magnesium aspartate in the treatment of ischemic arrhythmia in elderly patients and its effect on cardiac function. Methods The clinical data of98 elderly patients with ischemic arrhythmia who received treatment in the Department of Cardiology, Ankang Central Hospital from August 2016 to September 2017 were retrospectively analyzed. The patients were divided into control group and observation group(49 cases each) to receive metoprolol alone and metoprolol combined with potassium magnesium aspartate, respectively. The course of treatment was one month. The clinical effect and dynamic electrocardiogram were compared, and the cardiac function index and arrhythmia index of patients before and after treatment were compared between the two groups. Results The clinical total effective rate of the observation group(95.92%) was significantly higher than that of the control group(81.63%) after treatment. The total effective rate of dynamic electrocardiogram in the observation group was 91.84%, which was significantly higher than 83.67% in the control group(P<0.05).After treatment, the left ventricular end-systolic diameter of the observation group was(44.78±6.42) mm, which was significantly lower than(50.58±6.83) mm of the control group. The cardiac output and left ventricular ejection fraction were(5.30±0.97) L/min and(41.29±8.56)%, respectively, which were significantly higher than(4.60±0.89) L/min and(31.86±5.93)% of the control group(P<0.05). After treatment, the decreasing of number in atrial premature beat, ventricular premature beat, and junctional premature beat in the observation group were(1 621±354) times/24 h,(1 291±109) times/24 h,(117±34) times/24 h, which were significantly higher than(3 200±457)/24 h,(2 469±360)/24 h,(262±46) times/24 h in the control group(P<0.05). Conclusion Metoprolol combined with potassium magnesium aspartate in the treatment of elderly patients with ischemic arrhythmia is beneficial to improve the heart function of patients, and the clinical treatment effect is significant, which is worthy of clinical promotion.
Objective To explore the efficacy of metoprolol combined with potassium magnesium aspartate in the treatment of ischemic arrhythmia in elderly patients and its effect on cardiac function. Methods The clinical data of98 elderly patients with ischemic arrhythmia who received treatment in the Department of Cardiology, Ankang Central Hospital from August 2016 to September 2017 were retrospectively analyzed. The patients were divided into control group and observation group(49 cases each) to receive metoprolol alone and metoprolol combined with potassium magnesium aspartate, respectively. The course of treatment was one month. The clinical effect and dynamic electrocardiogram were compared, and the cardiac function index and arrhythmia index of patients before and after treatment were compared between the two groups. Results The clinical total effective rate of the observation group(95.92%) was significantly higher than that of the control group(81.63%) after treatment. The total effective rate of dynamic electrocardiogram in the observation group was 91.84%, which was significantly higher than 83.67% in the control group(P<0.05).After treatment, the left ventricular end-systolic diameter of the observation group was(44.78±6.42) mm, which was significantly lower than(50.58±6.83) mm of the control group. The cardiac output and left ventricular ejection fraction were(5.30±0.97) L/min and(41.29±8.56)%, respectively, which were significantly higher than(4.60±0.89) L/min and(31.86±5.93)% of the control group(P<0.05). After treatment, the decreasing of number in atrial premature beat, ventricular premature beat, and junctional premature beat in the observation group were(1 621±354) times/24 h,(1 291±109) times/24 h,(117±34) times/24 h, which were significantly higher than(3 200±457)/24 h,(2 469±360)/24 h,(262±46) times/24 h in the control group(P<0.05). Conclusion Metoprolol combined with potassium magnesium aspartate in the treatment of elderly patients with ischemic arrhythmia is beneficial to improve the heart function of patients, and the clinical treatment effect is significant, which is worthy of clinical promotion.
引文
[1]盛望,刘侃,王瑾茜,等.柴胡三参胶囊对缺血性心律失常大鼠钠通道稳态失活及再恢复的影响[J].中国中医急症,2016,25(1):42-91.
[2]母文利,王萍.稳心颗粒联合美托洛尔和门冬氨酸钾镁盐治疗老年缺血性心律失常临床效果及安全性分析[J].解放军医药杂志,2018,30(4):79-82.
[3]郭梦,胥雪莲,周晓莉.果糖二磷酸钠对缺血心肌围手术期保护作用观察[J].西部医学,2017,29(3):343-350.
[4]李春杰.门冬氨酸钾镁联合胺碘酮治疗急性心肌梗死室性心律失常临床研究[J].中国药业,2017,26(10):60-62.
[5]吉芳芳.老年缺血性心律失常患者应用稳心颗粒联合美托洛尔治疗的临床效果观察[J].基层医学论坛,2016,20(9):1204-1205.
[6]黄岩,杨红霞,左东挥.美托洛尔联合稳心颗粒对老年缺血性心律失常的治疗分析[J].世界最新医学信息文摘,2016,16(96):154-155.
[7]罗文娥.美托洛尔联合稳心颗粒治疗老年缺血性心律失常患者的有效性[J].中国继续医学教育,2017,9(1):190-191.
[8]项颖,冯丹,刘永宏,等.急性脑梗死合并冠心病患者血压变化与心脑缺血事件的相关性研究[J].西部医学,2018,30(3):374-384.
[9]周和寅.稳心颗粒联合美托洛尔治疗老年人冠心病心律失常的临床疗效研究[J].当代医学,2016,22(27):152-153.
[10]胡维政.稳心颗粒与美托洛尔治疗冠心病合并室性心律失常的随机对照评价[J].中国继续医学教育,2016,8(12):159-160.
[11]高敏,李延宇.家庭照料对老年人健康水平影响的效应分析研究[J].江苏大学学报(社会科学版),2016,18(4):63-73.
[12]范红绢,陈辉.基于城市居民意愿的养老政策研究--以南京市为例[J].江苏大学学报(社会科学版),2018,20(1):62-70.
[13]赵梅,郭振丰,李天时,等.丹参酮ⅡA对大鼠实验性心肌梗死心律失常机制研究[J].中国医院药学杂志,2016,36(17):1452-1455.
[14]全虎杰,王丽红,刘晓辉.分析美托洛尔联合稳心颗粒治疗老年缺血性心律失常的临床效果[J].中国实用医药,2018,13(4):3-5.
[15]杨洋.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的临床疗效[J].中国医药指南,2016,14(24):74-75.
[16]何小君,罗贵全.稳心颗粒与胺碘酮联合酒石酸美托洛尔对冠心病心律失常患者心功能及血液流变学的影响[J].实用心脑肺血管病杂志,2017,25(9):137-139.
[17]尚娜荣.老年缺血性心律失常患者联用美托洛尔和稳心颗粒治疗的临床效果考察[J].中医临床研究,2017,9(9):35-37.
[18]乔树洲,刘丽华,贾彬莉,等.老年患者不同抗心律失常药物治疗的有效性与安全性分析[J].中国临床保健杂志,2017,20(3):271-273.
[19]董艳萍.稳心颗粒联合美托洛尔治疗老年冠心病心律失常的临床分析[J].北方药学,2017,14(2):181-182.
[20]杜佩珊.美托洛尔联合稳心颗粒对老年缺血性心律失常的治疗效果及对心功能影响观察[J].健康之路,2017,16(5):141-142.
[2]母文利,王萍.稳心颗粒联合美托洛尔和门冬氨酸钾镁盐治疗老年缺血性心律失常临床效果及安全性分析[J].解放军医药杂志,2018,30(4):79-82.
[3]郭梦,胥雪莲,周晓莉.果糖二磷酸钠对缺血心肌围手术期保护作用观察[J].西部医学,2017,29(3):343-350.
[4]李春杰.门冬氨酸钾镁联合胺碘酮治疗急性心肌梗死室性心律失常临床研究[J].中国药业,2017,26(10):60-62.
[5]吉芳芳.老年缺血性心律失常患者应用稳心颗粒联合美托洛尔治疗的临床效果观察[J].基层医学论坛,2016,20(9):1204-1205.
[6]黄岩,杨红霞,左东挥.美托洛尔联合稳心颗粒对老年缺血性心律失常的治疗分析[J].世界最新医学信息文摘,2016,16(96):154-155.
[7]罗文娥.美托洛尔联合稳心颗粒治疗老年缺血性心律失常患者的有效性[J].中国继续医学教育,2017,9(1):190-191.
[8]项颖,冯丹,刘永宏,等.急性脑梗死合并冠心病患者血压变化与心脑缺血事件的相关性研究[J].西部医学,2018,30(3):374-384.
[9]周和寅.稳心颗粒联合美托洛尔治疗老年人冠心病心律失常的临床疗效研究[J].当代医学,2016,22(27):152-153.
[10]胡维政.稳心颗粒与美托洛尔治疗冠心病合并室性心律失常的随机对照评价[J].中国继续医学教育,2016,8(12):159-160.
[11]高敏,李延宇.家庭照料对老年人健康水平影响的效应分析研究[J].江苏大学学报(社会科学版),2016,18(4):63-73.
[12]范红绢,陈辉.基于城市居民意愿的养老政策研究--以南京市为例[J].江苏大学学报(社会科学版),2018,20(1):62-70.
[13]赵梅,郭振丰,李天时,等.丹参酮ⅡA对大鼠实验性心肌梗死心律失常机制研究[J].中国医院药学杂志,2016,36(17):1452-1455.
[14]全虎杰,王丽红,刘晓辉.分析美托洛尔联合稳心颗粒治疗老年缺血性心律失常的临床效果[J].中国实用医药,2018,13(4):3-5.
[15]杨洋.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的临床疗效[J].中国医药指南,2016,14(24):74-75.
[16]何小君,罗贵全.稳心颗粒与胺碘酮联合酒石酸美托洛尔对冠心病心律失常患者心功能及血液流变学的影响[J].实用心脑肺血管病杂志,2017,25(9):137-139.
[17]尚娜荣.老年缺血性心律失常患者联用美托洛尔和稳心颗粒治疗的临床效果考察[J].中医临床研究,2017,9(9):35-37.
[18]乔树洲,刘丽华,贾彬莉,等.老年患者不同抗心律失常药物治疗的有效性与安全性分析[J].中国临床保健杂志,2017,20(3):271-273.
[19]董艳萍.稳心颗粒联合美托洛尔治疗老年冠心病心律失常的临床分析[J].北方药学,2017,14(2):181-182.
[20]杜佩珊.美托洛尔联合稳心颗粒对老年缺血性心律失常的治疗效果及对心功能影响观察[J].健康之路,2017,16(5):141-142.